ClinicalTrials.gg
CompletedNCT01170065Updated Jun 6, 2019Results posted

Roll Over Study From 1199.30 BIBF 1120 in Idiopathic Pulmonary Fibrosis (IPF)

A Phase 2 interventional study of BIBF 1120 and BIBF 1120 in Pulmonary Fibrosis, sponsored by Boehringer Ingelheim. Completed at 58 sites in 21 countries. Open to participants aged 40 Years and older. Per ClinicalTrials.gov, last updated 2019-06-06.

Sponsored by Boehringer Ingelheim · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
198
Allocation
Non-randomized
Ages
40 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 31 studies in Pulmonary Fibrosis with a site in Italy — 11 open to participants now, 16 under way, 4 of them phase 3. Pulmonary Fibrosis · Italy.

Enrollment
11th of 17
198 · median 320
Started
2010
the only one that year
Phase 2
8 of 31
none open now
Registered
5th of 31
by date
Lead sponsor
3 of 31
Boehringer Ingelheim

Among the 31 studies in Pulmonary Fibrosis with a site in Italy, this one is the 11th largest by enrollment of the 17 interventional ones that give a count, is the only one that started in 2010, is one of 8 in phase 2, and was the 5th registered.

Pulmonary Fibrosis

342 studies on the registry are indexed under Pulmonary Fibrosis; 98 are open to participants now.

Browse Pulmonary Fibrosis studies →

Open to participants now

11 of the 31 studies in Pulmonary Fibrosis with a site in Italy are open now. Recruiting first, the newest first:

6 more — sign in →

All 11 open studies →

A study can be open while its sites in Italy have not opened yet or have stopped. Only those recruiting at a site in Italy →

Who these studies take

Of the 71 Pulmonary Fibrosis studies recruiting now, 41 (58%) set no upper age limit and 4 (6%) stop at 75 or younger; 8 take children under 18; 12 take healthy volunteers.

This study: 40 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 31 studies in Pulmonary Fibrosis with a site in Italy, or all of them as a file.
02

Study summary

The aim of this trial is to offer continuation of BIBF 1120 treatment for patients with Idiopathic Pulmonary Fibrosis (IPF) who have completed a prior clinical trial with that drug.

The primary objective will be to establish the long term tolerability and safety profile of BIBF 1120 in Idiopathic Pulmonary Fibrosis (IPF).

As a secondary objective the effects of long term treatment with BIBF 1120 on survival as well as safety and efficacy parameters will be investigated in an open-label, not randomized, un-controlled design.

03

Conditions studied

  • Pulmonary Fibrosis

Browse trials for

04

Who can participate

Ages eligible
40 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Patient with a primary diagnosis of IPF (according to the 2000 American Thoracic Society/European Respiratory Society (ATS/ERS) criteria, who are willing to continue trial medication.
  2. Written signed prior to entry into the study, in accordance with International Conference on Harmonisation-Good Clinical Practice (ICH-GCP) and local law
  3. Completion of 1199.30 study and still under treatment (i.e. not discontinued in parent trial)

Exclusion criteria

Exclusion criteria:

  1. Any disease that may put the patient at risk when participating in this trial. Reconsider carefully all exclusion criteria of trial 1199.30. However, patients may qualify for participation even though exclusion criteria may have been met during the course of participation in 1199.30, if the investigator's benefit-risk assessment remains favourable.
  2. Participation in another experimental clinical trial (except 1199.30) in the last 8 weeks.
  3. Women who are breast feeding or of child bearing potential not using a highly effective method of for at least one month prior to inclusion and at least 10 weeks after end of active therapy.

    Highly effective methods of birth control are defined as those which result in a low failure rate (i.e. less than 1 % per year) when used consistently and correctly, such as implants, injectables, combined oral contraceptives, some Intra Uterine Devices (IUDs), sexual abstinence or vasectomized partner. Female patients will be considered of unless surgically sterilized by hysterectomy or bilateral tubal ligation, or for at least two years.

  4. Sexually active males not committing to using condoms during the course of the study and at least 10 weeks after the end of active therapy (except if their partner is not of childbearing potential).
  5. Patients who require full-dose anticoagulation (e.g. vitamin K antagonists, heparin, hirudin etc).
  6. Patients who require full-dose antiplatelet (e.g. acetyl salicylic acid, clopidogrel etc) therapy.
  7. Known or suspected active alcohol or drug abuse.
  8. Patient not compliant in previous trial, with trial medication or trial visits.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
198 participants (actual)

Study arms

  • Experimental
    BIBF 1120 low qd

    Low dose BIBF 1120 once daily

    Drug: BIBF 1120

  • Experimental
    BIBF 1120 low bid

    Low dose BIBF 1120 twice daily

    Drug: BIBF 1120

  • Experimental
    BIBF 1120 medium bid

    Intermediate dose BIBF 1120 twice daily

    Drug: BIBF 1120

  • Experimental
    BIBF 1120 high bid

    High dose BIBF 1120 twice daily

    Drug: BIBF 1120

Interventions

  • Intermediate dose BIBF 1120 twice daily

  • High dose BIBF 1120 twice daily

  • Low dose BIBF 1120 twice daily

  • Low dose BIBF 1120 once daily

06

What researchers measure

Primary outcomes

  1. Annual Rate of Decline in Forced Vital Capacity (FVC)

    Forced vital capacity (FVC) is the total amount of air exhaled during the lung function test. For this endpoint reported means represent the adjusted rate.

    Time frame: From first drug administration in 1199.35 until database lock 15Oct2015, up to 61.8 Months

Secondary outcomes

  1. Overall Survival

    Overall survival is defined as the time from the first intake of nintedanib in trial 1199.35 to death. For presentation of overall survival results, Kaplan-Meier estimates and confidence intervals (using Greenwood variance formula) for the overall on-treatment survival is calculated within each treatment arm.

    Time frame: From first drug administration in 1199.35 until database lock 15Oct2015, up to 61.8 Months

  2. Progression-Free Survival

    Progression-free survival was defined as the time from the first nintedanib intake in trial 1199.35 to disease progression. For presentation of progression-free survival results, Kaplan-Meier estimates and confidence intervals (using Greenwood variance formula) for the overall on-treatment progression-free survival is calculated within each treatment arm.

    Time frame: From first trial drug intake in 1199.35 to disease progression; up to 61.8 months

  3. Annual Rate of Decline in Haemoglobin Corrected Diffusing Capacity of the Lung for Carbon Monoxide (DLCO) Decrease

    Haemoglobin corrected DLCO decrease was a secondary endpoint for the trial. It was considered important that all investigators used the same method of testing and recording data at each visit for each patient. Haemoglobin corrected DLCO was calculated for each patient using the following formulae: Males: Hb corrected DLCO = measured DLCO x (10.22 + Hb concentration) / (1.7 x Hb concentration) Females: Hb corrected DLCO = measured DLCO x (9.38 + Hb concentration) / (1.7 x Hb concentration). Annual rate of decline in haemoglobin corrected diffusing capacity of the lung for carbon monoxide (DLCO) decrease is presented.

    Time frame: From first drug administration in 1199.35 until database lock 15Oct2015, up to 61.8 Months

  4. Percentage of Patients With at Least One Acute Idiopathic Pulmonary Fibrosis (IPF) Exacerbation

    Percentage of patients with at least one acute idiopathic pulmonary fibrosis (IPF) exacerbation are presented. An exacerbation was defined as otherwise unexplained clinical features occurring within 1 month including all of the following: * Progression of dyspnoea over several days to 4 weeks * New diffuse pulmonary infiltrates on chest X-ray and/or high-resolution computerised tomography (HRCT) Parenchymal abnormalities with no pneumothorax or pleural effusion (new ground-glass opacities) since the last visit * A decrease in arterial oxygen partial pressure (PaO2) of ≥10 mmHg or PaO2/fraction of inspired oxygen (FiO2) of \<225 mmHg since the last visit * Exclusion of infection based on routine clinical practice and microbiological studies * Absence of other contributory causes such as congestive heart failure, pulmonary embolism, etc.

    Time frame: From first drug administration in 1199.35 until database lock 15Oct2015, up to 61.8 Months

  5. Incidence of Patients With at Least One Acute IPF Exacerbation Over Time

    Incidence rate = (Patients with at least one acute IPF exacerbation / Total number of years at risk) x 100

    Time frame: From first drug administration in 1199.35 until database lock 15Oct2015, up to 61.8 Months

  6. Time to First Acute IPF Exacerbation

    Due to rare events, the median of time to event is not calculable, thus Kaplan-Meier estimates (providing the percentage of patients without acute IPF exacerbation for a certain amount of time after treatment) and confidence intervals (using Greenwood variance formula) are reported and presented within each treatment arm as secondary endpoint.

    Time frame: From first drug administration in 1199.35 until database lock 15Oct2015, up to 61.8 Months

  7. Percentage of Patients With at Least One Adverse Events (AEs), With Investigator Defined Drug-Related AEs, AEs Leading to Discontinuation of Trial Drug, Serious AEs

    Percentage of patients with at least one Adverse events (AEs), with investigator defined drug-related AEs, AEs leading to discontinuation of trial drug, serious AEs are presented

    Time frame: From the first nintedanib intake in trial 1199.35 to the last nintedanib intake + 28 days; up to 61.8 months + 28 days

07

Results

Posted Jun 6, 2019

Participant flow

Treatment groups are displayed according to dose at randomisation in 1199.30 (NCT00514683).

Participant flow — Overall Study
MilestonePlaceboNintedanib 50 mg- 100 mgNintedanib 150 mg
Started3712635
Completed9349
Not completed289226
Withdrew: Adverse event175010
Withdrew: Lost to follow-up141
Withdrew: Consent withdrawn, not due to ae242
Withdrew: Reason other than specified383
Withdrew: Ongoing after planned observation time52610

Outcome measures

PrimaryAnnual Rate of Decline in Forced Vital Capacity (FVC)

Forced vital capacity (FVC) is the total amount of air exhaled during the lung function test. For this endpoint reported means represent the adjusted rate.

Time frame:
From first drug administration in 1199.35 until database lock 15Oct2015, up to 61.8 Months
Reported as:
Mean · milliliters per year (mL/ yr)
Annual Rate of Decline in Forced Vital Capacity (FVC)
milliliters per year (mL/ yr)PlaceboNintedanib 50 mg- 100 mgNintedanib 150 mg
Annual Rate of Decline in Forced Vital Capacity (FVC)-129.0 ± 29.47-137.5 ± 14.60-132.9 ± 28.22
SecondaryOverall Survival

Overall survival is defined as the time from the first intake of nintedanib in trial 1199.35 to death. For presentation of overall survival results, Kaplan-Meier estimates and confidence intervals (using Greenwood variance formula) for the overall on-treatment survival is calculated within each treatment arm.

Time frame:
From first drug administration in 1199.35 until database lock 15Oct2015, up to 61.8 Months
Reported as:
Number · percentage of participants
Overall Survival
percentage of participantsPlaceboNintedanib 50 mg- 100 mgNintedanib 150 mg
Overall Survival37.4 ± 29.4746.8 ± 14.6066.2 ± 28.22
SecondaryProgression-Free Survival

Progression-free survival was defined as the time from the first nintedanib intake in trial 1199.35 to disease progression. For presentation of progression-free survival results, Kaplan-Meier estimates and confidence intervals (using Greenwood variance formula) for the overall on-treatment progression-free survival is calculated within each treatment arm.

Time frame:
From first trial drug intake in 1199.35 to disease progression; up to 61.8 months
Reported as:
Number · percentage of participants
Progression-Free Survival
percentage of participantsPlaceboNintedanib 50 mg- 100 mgNintedanib 150 mg
Progression-Free Survival9.6 ± 29.473.5 ± 14.6012.2 ± 28.22
SecondaryAnnual Rate of Decline in Haemoglobin Corrected Diffusing Capacity of the Lung for Carbon Monoxide (DLCO) Decrease

Haemoglobin corrected DLCO decrease was a secondary endpoint for the trial. It was considered important that all investigators used the same method of testing and recording data at each visit for each patient. Haemoglobin corrected DLCO was calculated for each patient using the following formulae: Males: Hb corrected DLCO = measured DLCO x (10.22 + Hb concentration) / (1.7 x Hb concentration) Females: Hb corrected DLCO = measured DLCO x (9.38 + Hb concentration) / (1.7 x Hb concentration). Annual rate of decline in haemoglobin corrected diffusing capacity of the lung for carbon monoxide (DLCO) decrease is presented.

Time frame:
From first drug administration in 1199.35 until database lock 15Oct2015, up to 61.8 Months
Reported as:
Mean · mmol/min/kPa/yr
Annual Rate of Decline in Haemoglobin Corrected Diffusing Capacity of the Lung for Carbon Monoxide (DLCO) Decrease
mmol/min/kPa/yrPlaceboNintedanib 50 mg- 100 mgNintedanib 150 mg
Annual Rate of Decline in Haemoglobin Corrected Diffusing Capacity of the Lung for Carbon Monoxide (DLCO) Decrease-0.4 ± 0.08-0.3 ± 0.04-0.2 ± 0.07
SecondaryPercentage of Patients With at Least One Acute Idiopathic Pulmonary Fibrosis (IPF) Exacerbation

Percentage of patients with at least one acute idiopathic pulmonary fibrosis (IPF) exacerbation are presented. An exacerbation was defined as otherwise unexplained clinical features occurring within 1 month including all of the following: * Progression of dyspnoea over several days to 4 weeks * New diffuse pulmonary infiltrates on chest X-ray and/or high-resolution computerised tomography (HRCT) Parenchymal abnormalities with no pneumothorax or pleural effusion (new ground-glass opacities) since the last visit * A decrease in arterial oxygen partial pressure (PaO2) of ≥10 mmHg or PaO2/fraction of inspired oxygen (FiO2) of \<225 mmHg since the last visit * Exclusion of infection based on routine clinical practice and microbiological studies * Absence of other contributory causes such as congestive heart failure, pulmonary embolism, etc.

Time frame:
From first drug administration in 1199.35 until database lock 15Oct2015, up to 61.8 Months
Reported as:
Number · Percentage of participants
Percentage of Patients With at Least One Acute Idiopathic Pulmonary Fibrosis (IPF) Exacerbation
Percentage of participantsPlaceboNintedanib 50 mg- 100 mgNintedanib 150 mg
Percentage of Patients With at Least One Acute Idiopathic Pulmonary Fibrosis (IPF) Exacerbation13.5 ± 0.0819.8 ± 0.0420.0 ± 0.07
SecondaryIncidence of Patients With at Least One Acute IPF Exacerbation Over Time

Incidence rate = (Patients with at least one acute IPF exacerbation / Total number of years at risk) x 100

Time frame:
From first drug administration in 1199.35 until database lock 15Oct2015, up to 61.8 Months
Reported as:
Number · Exacerbations Per Year
Incidence of Patients With at Least One Acute IPF Exacerbation Over Time
Exacerbations Per YearPlaceboNintedanib 50 mg- 100 mgNintedanib 150 mg
Incidence of Patients With at Least One Acute IPF Exacerbation Over Time6.1 ± 0.087.6 ± 0.047.8 ± 0.07
SecondaryTime to First Acute IPF Exacerbation

Due to rare events, the median of time to event is not calculable, thus Kaplan-Meier estimates (providing the percentage of patients without acute IPF exacerbation for a certain amount of time after treatment) and confidence intervals (using Greenwood variance formula) are reported and presented within each treatment arm as secondary endpoint.

Time frame:
From first drug administration in 1199.35 until database lock 15Oct2015, up to 61.8 Months
Reported as:
Number · percentage of participants
Time to First Acute IPF Exacerbation
percentage of participantsPlaceboNintedanib 50 mg- 100 mgNintedanib 150 mg
Time to First Acute IPF Exacerbation67.7 ± 29.4768.6 ± 14.6073.5 ± 28.22
SecondaryPercentage of Patients With at Least One Adverse Events (AEs), With Investigator Defined Drug-Related AEs, AEs Leading to Discontinuation of Trial Drug, Serious AEs

Percentage of patients with at least one Adverse events (AEs), with investigator defined drug-related AEs, AEs leading to discontinuation of trial drug, serious AEs are presented

Time frame:
From the first nintedanib intake in trial 1199.35 to the last nintedanib intake + 28 days; up to 61.8 months + 28 days
Reported as:
Number · Percentage of participants
Percentage of Patients With at Least One Adverse Events (AEs), With Investigator Defined Drug-Related AEs, AEs Leading to Discontinuation of Trial Drug, Serious AEs
Percentage of participantsPlaceboNintedanib 50 mg- 100 mgNintedanib 150 mg
AEs100.0 ± 0.0899.2 ± 0.0497.1 ± 0.07
Investigator defined drug-related AEs70.365.954.3
AEs leading to discontinuation of trial drug48.641.334.3
Serious AE67.674.662.9

Adverse events

Collected over From the first nintedanib intake in trial 1199.35 to the last nintedanib intake + 28 days; up to 61.8 months + 28 days. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo—25/37 (67.6%)34/37 (91.9%)
Nintedanib 50 mg- 100 mg—94/126 (74.6%)111/126 (88.1%)
Nintedanib 150 mg—22/35 (62.9%)32/35 (91.4%)
Most frequent serious events
Showing 10 of 145
Most frequent serious events
EventPlaceboNintedanib 50 mg- 100 mgNintedanib 150 mg
Idiopathic pulmonary fibrosisRespiratory, thoracic and mediastinal disorders11/3741/12610/35
DyspnoeaRespiratory, thoracic and mediastinal disorders2/3711/1260/35
Lung infectionInfections and infestations1/375/1263/35
DiarrhoeaGastrointestinal disorders3/372/1261/35
PneumoniaInfections and infestations3/376/1262/35
FallInjury, poisoning and procedural complications3/372/1261/35
Cardiac disorderCardiac disorders0/370/1262/35
Respiratory failureRespiratory, thoracic and mediastinal disorders1/377/1261/35
Cardiac arrestCardiac disorders2/371/1260/35
HaemorrhoidsGastrointestinal disorders2/371/1260/35
Most frequent other events
Showing 10 of 59
Most frequent other events
EventPlaceboNintedanib 50 mg- 100 mgNintedanib 150 mg
DiarrhoeaGastrointestinal disorders19/3768/12622/35
BronchitisInfections and infestations12/3727/1266/35
Weight decreasedInvestigations10/3729/1267/35
NauseaGastrointestinal disorders9/3722/1262/35
NasopharyngitisInfections and infestations8/3724/1266/35
CoughRespiratory, thoracic and mediastinal disorders3/3727/1264/35
VomitingGastrointestinal disorders7/3717/1263/35
Idiopathic pulmonary fibrosisRespiratory, thoracic and mediastinal disorders0/3722/1263/35
InfluenzaInfections and infestations1/379/1266/35
Decreased appetiteMetabolism and nutrition disorders6/3717/1262/35

Baseline characteristics

Treated set (TS): The treated set which included all patients who received at least 1 dose of open-label study medication in trial 1199.35

Age, Continuous
Age, Continuous(years)PlaceboNintedanib 50 mg- 100 mgNintedanib 150 mgTotal
Mean64.2 ± 7.365.4 ± 8.665.2 ± 7.265.2 ± 8.1
Sex: Female, Male
Sex: Female, Male(Participants)PlaceboNintedanib 50 mg- 100 mgNintedanib 150 mgTotal
Female1436757
Male239028141
08

Study locations

58 sites
  • INSARES
    Mendoza, M5500CCG, Argentina
  • Respiratory Clinical Trial Pty Ltd.
    Glen Osmond, South Australia 5064, Australia
  • The Queen Elizabeth Hospital
    Woodville, South Australia 5011, Australia
  • Royal Perth Hospital-Lung Transplant Unit
    Perth, Western Australia 6000, Australia
  • ULB Hopital Erasme
    Bruxelles, 1070, Belgium
  • UZ Leuven
    Leuven, 3000, Belgium
  • Yvoir - UNIV UCL de Mont-Godinne
    Yvoir, 5530, Belgium
  • Irmandade Santa Casa de Misericordia de Porto Alegre
    Porto Alegre, CEP90035-0, Brazil
  • Special. Hospital for Active Treatment, Sv. Sofia 2nd Clinic
    Sofia, 1431, Bulgaria
  • QEII Health Sciences Centre (Dalhousie University)
    Halifax, Nova Scotia B3H 3A7, Canada
  • St. Joseph's Healthcare Hamilton
    Hamilton, Ontario L8N 4A6, Canada
  • Instituto Nacional del Tórax
    Santiago, 7500000, Chile
  • Beijing Chao-Yang Hospital
    Beijing, 100020, China
  • Peking Union Medical College Hospital
    Beijing, 100730, China
  • Nanjing Drum Tower Hospital
    Nanjing, 210008, China
  • Shanghai Pulmonary Hospital
    Shanghai, 200433, China
  • University Hospital Na Bulovce, Prague
    Prague 8, 180 81, Czechia
  • Masaryk Hospital, Usti nad Labem
    Usti nad Labem, 401 13, Czechia
  • HOP Avicenne
    Bobigny, 93009, France
  • HOP Dijon, Pneumo, Dijon
    DIJON Cedex, 21079, France
  • HOP Calmette
    Lille Cedex, 59037, France
  • HOP Calmette
    Lille, 59037, France
  • HOP Arnaud de Villeneuve
    Montpellier, 34295, France
  • HOP Pasteur
    Nice Cedex 1, 06002, France
  • HOP Bichat
    Paris Cedex 18, 75877, France
  • Klinik Donaustauf
    Donaustauf, 93093, Germany
  • Ruhrlandklinik, Westdeutsches Lungenzentrum am Universitätsklinikum Essen gGmbH
    Essen, 45239, Germany
  • Universitätsklinikum Freiburg
    Freiburg/Breisgau, 79106, Germany
  • Pneumologisches Forschungsinstitut an der LungenClinic Grosshansdorf GmbH
    Großhansdorf, 22927, Germany
  • Universitätsmedizin der Johannes Gutenberg-Universität Mainz
    Mainz, 55131, Germany
  • Klinikum der Universität München - Campus Großhadern
    München, 81377, Germany
  • University General Hospital of Evros
    Alexandroupolis, 68100, Greece
  • University Hospital of Heraklion, University Pulmonology Cl
    Heraklion, 71100, Greece
  • Csongrad County's Hosp.
    Deszk, 6772, Hungary
  • University of Pecs, 1st internal Med. Dept., Pulmonology
    Pecs, 7623, Hungary
  • Mater Misericordiae University Hospital
    Dublin, 7, Ireland
  • Ospedale C. G. Mazzoni
    Ascoli Piceno, 63100, Italy
  • Osp. S. Giuseppe Fatebenefratelli
    Milano, 20123, Italy
  • Università di Modena e Reggio Emilia
    Modena, 41100, Italy
  • Università Federico II
    Napoli, 80131, Italy
  • Pol. Universitario Tor Vergata
    Roma, 00133, Italy
  • A.O.U. Senese Policlinico Santa Maria alle Scotte
    Siena, 53100, Italy
  • Università di Perugia
    Terni, 05100, Italy
  • Ospedale di Cattinara
    Trieste, 34100, Italy
  • Instituto Nacional de Enfermedades Respiratorias Ismael Cosío Villegas
    Distrito Federal, 14080, Mexico
  • St. Antonius ziekenhuis, locatie Nieuwegein
    Nieuwegein, 3435 CM, Netherlands
  • CHUC - Centro Hospitalar e Universitário de Coimbra, EPE
    Coimbra, 3041-801, Portugal
  • CHLN, EPE - Hospital de Santa Maria
    Lisboa, 1064-035, Portugal
  • Centro Hospitalar Lisboa Norte Hospital Pulido Valente
    Lisboa, 1750-001 L, Portugal
  • Centro Hospitalar São João,EPE
    Porto, 4202-451, Portugal
  • Central Scientific Research Insitute of Tuberculosis
    Moscow, 107564, Russian Federation
  • Scientific Research Institute of Pulmonology
    St. Petersburg, 197089, Russian Federation
  • Hospital Vall d'Hebron
    Barcelona, 08035, Spain
  • Hospital Dr. Peset
    Valencia, 46017, Spain
  • Queen Elizabeth Hospital
    Birmingham, B15 2GW, United Kingdom
  • Birmingham Heartlands Hospital
    Birmingham, B9 5SS, United Kingdom
  • The Medicines Evaluation Unit
    Manchester, M23 9QZ, United Kingdom
  • Southmead Hospital
    Westbury On Trym, BS10 5NB, United Kingdom
09

References and documents

Publications

  • Richeldi L, Kreuter M, Selman M, Crestani B, Kirsten AM, Wuyts WA, Xu Z, Bernois K, Stowasser S, Quaresma M, Costabel U. Long-term treatment of patients with idiopathic pulmonary fibrosis with nintedanib: results from the TOMORROW trial and its open-label extension. Thorax. 2018 Jun;73(6):581-583. doi: 10.1136/thoraxjnl-2016-209701. Epub 2017 Oct 9. PubMed 28993537 ↗
10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jun 2010 to primary completion in Sep 2016, 75 months.

Results were first posted in Jun 2019, 2 years 8 months after primary completion.

Of 33 phase 2 interventional studies under Pulmonary Fibrosis, half reached primary completion within 44 months of starting (the median), counting those still running; a quarter within 27 and three quarters within 75. This study's 75 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 6, 2010
First posted
Jul 27, 2010
StartActual
Jun 25, 2010
Primary completionActual
Sep 26, 2016
CompletionActual
Sep 26, 2016
Results first posted
Jun 6, 2019
Last update
Jun 6, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 6, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01170065
Responsible party
Sponsor
First posted
Jul 27, 2010
Start date
Jun 25, 2010
Primary completion
Sep 26, 2016
Completion
Sep 26, 2016
Results posted
Jun 6, 2019
Last update
Jun 6, 2019

Study contacts

Boehringer Ingelheim
study chair · Boehringer Ingelheim
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Nintedanib

Start the discussion